Pharmaceuticals, Biotechnology and Life Sciences
Santhera Pharmaceuticals has revealed that AGAMREE (vamorolone) has received approval in the United Kingdom (UK) for treating Duchenne muscular dystrophy (DMD) in patients aged 4 and above, regardless of the underlying mutation and ambulatory status.
CHMP has adopted a positive opinion in favor of approval of a Swiss specialty pharmaceutical company Santhera Pharmaceuticals’ AGAMREE (vamorolone) for the treatment of Duchenne Muscular Dystrophy patients aged 4 years and older.
Santhera Pharmaceuticals (SIX: SANN) has appointed Shabir Hasham, MD, as Chief Medical Officer (CMO) and a member of Santhera’s Executive Management team, effective May 1, 2022.
Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc (US: private) have announced the initiation of a rolling new drug application (NDA) submission to the U.S. Food and Drug Administration (FDA) for vamorolone for the treatment of Duchenne muscular dystrophy (DMD). Vamorolone for DMD has been granted Fast Track Designation by the FDA.
Santhera Pharmaceuticals has announced a cahs boost with an oversubscribed equity financing of CHF 20 million, a placement of private convertible bonds of CHF 15 million and upsizing of an existing financing arrangement of up to CHF 10 million.
Santhera Pharmaceuticals’s Raxone has been renewed in UK, as the nation’s Medicines and Healthcare products Regulatory Agency (MHRA) has renewed…
Santhera Pharmaceuticals said on Tuesday that the Korean Ministry of Food and Drug Safety (MFDS) has accepted its new drug…